Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-861 Phase 3 in narcolepsy type 1 (China cohort)
CTR20243927Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oveporexton in narcolepsy type 1 (NT1), sponsored by Takeda. Started Nov 2024; status: completed.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on CTR20243927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243927.